The decision by Johnson and Johnson to recommend a cessation of use by U.S. health agencies Covid-19 vaccine Experts warn that while all coronavirus jabs can be quickly reversed, there is a risk of damaging public confidence.
U.S. public health agencies and drug regulators have issued a Joint alert On Monday, healthcare providers called for a temporary halt to the use of the J&J vaccine, citing six reports of “rare and severe” blood clots in the United States in cases where “six million people have received it.”
The intervention prompted the country’s two largest pharmacy chains, Walgreens and CVS, and several states in the United States to immediately stop administering J&J doses.
Officials stressed Monday that there will be minimal impact on U.S. supplies, most of which are sourced from Bioentech / Pfizer and Modarna. But experts say agencies are advising health workers to resume use J&J Shots in the days to come, irreparable damage can be gained not only by that vaccine, but by all covid inoculations.
Jake Emanuel, a professor of healthcare at the University of Pennsylvania and a former coronavirus adviser to US President Joe Biden, said: “I understand they wanted to be transparent, but did they really have to announce a full break?
“My concern is that it will unnecessarily reduce confidence in the vaccine and possibly everything. [Covid-19] Vaccines. Will people know the difference? “
Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security in Baltimore, said: “The damage has been done, it is going to be difficult to start again. All [the CDC] How rare is this, how safe and effective is the J&J vaccine? But this move is going to be difficult to reverse. “
The recommendation to suspend the use of the J&J vaccine came amid some indications that supplies are exceeding demand in several states, with potential shelters for carnivirus JB.
Mississippi, for example, handles 63 percent of the doses it receives, according to the latest state data, and Alabama uses only 66 percent of its allocation. That compares with 91 percent of New York’s supply.
A committee of public health experts will meet Thursday to recommend whether the Centers for Disease Control and Prevention should change its advice on the J&J vaccine permanently. Although individual states and health practitioners are responsible for deciding which shots to give, they mostly follow the CDC’s national guidelines.
Anthony Fawcett, head of the department at the National Institute of Allergy and Infectious Diseases, said Monday that the final decision on the J&J vaccine would be made “within a few weeks to weeks” and that this gap would not affect supply.
The J&J vaccine is only 4 percent of the dose administered so far in the United States. However it requires only a single shot and can be stored at normal refrigerator temperatures, making it an important tool for reaching remote and low-lying communities.
Jeff Gentes, co-ordinator of the White House Coronavirus Task Force, stressed that supply will remain stable in rural areas as well, but thanks to mobile units equipped to store Pfizer and modern vaccines.
Pfizer said Monday that it has recently increased production and will be able to deliver ten percent more doses by the end of May than previously planned.
Liz Hamel, who instructed the Kaiser Family Foundation Health Think Tank to vote, said: “We know that side effects are the biggest concern people have about vaccines. Anything that could potentially be seen as a side effect could make this concern even more significant. “
He added: “It’s not just the J&K vaccine that can be affected. Many people are not paying attention to the various options, and when they see a potential problem with a covid vaccine, especially if they are already concerned, they are less likely to get a shot. ”
When European medical regulators identified similar concerns about the AstraZeneca vaccine, which has been blamed for being rare but also serious. Blood clots, Polstars have mentioned the issue of vaccine hesitation.
After caution, Polster Yugov Report sharp decline There is a slight decrease in the perceived protection of the AZ vaccine and even in the perceived protection of others. In Germany, the number of people who believe the AZ vaccine is safe fell from 43 percent in February to 32 percent just a month later. In France, it dropped from 33 percent to 23 percent.
Vaccine confidence in the United States has improved over the past year, with 55 percent now saying they have either been vaccinated or will become as soon as possible. However, it still tells 22 percent of Americans that they want to “wait and see” before being vaccinated, 7 percent who say they will do it when they need work or other activities, and 15 percent who say they will not be vaccinated.
Of the 15 percent, 70 percent are white and 5 percent are Republican voters
Hamel said: “We are working our way through the‘ Wait and See ’group, and going against the stiff resistance of 15 per cent of people who simply do not deny. So far we have not received any message that works with them, but it is unlikely to help.